Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
163 articles by Michael Gibney
-
As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply
April 25, 2024 -
How pharma’s surging M&A is impacting the industry’s tech sector
April 11, 2024 -
Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
April 9, 2024 -
With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
April 4, 2024 -
A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough
April 2, 2024 -
‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field
March 28, 2024 -
Alnylam turns to genealogy to find rare disease patients through family trees
March 26, 2024 -
An ocean of answers in a single cell — how proteomics can lead to better drugs
March 21, 2024 -
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
March 19, 2024 -
Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
March 14, 2024 -
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
March 12, 2024 -
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
March 7, 2024 -
HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
March 5, 2024 -
Biogen partner NeuroSense seeks a role in the ALS revolution
Feb. 29, 2024 -
Can a top scientist and Moderna co-founder change the CRO game?
Feb. 28, 2024 -
AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma
Feb. 22, 2024 -
Biden or Trump: How deeply will 2024’s election outcome impact pharma?
Feb. 20, 2024 -
The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround
Feb. 15, 2024 -
‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity
Feb. 14, 2024 -
Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps
Feb. 8, 2024 -
‘Beginning of the end’ for small molecules? VCs brace for Medicare investment gap
Feb. 6, 2024 -
Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?
Feb. 1, 2024 -
Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?
Jan. 31, 2024 -
King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way
Jan. 25, 2024 -
J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff
Jan. 24, 2024